Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio osservazionale a lungo termine sull'efficacia e la sicurezza di Lecigon in pazienti con malattia di Parkinson avanzata (ELEGANCE)

1 ottobre 2026 aggiornato da: Britannia Pharmaceuticals Ltd.

ELEGANCE - Uno studio non interventistico sull'efficacia e la sicurezza a lungo termine del gel intestinale a base di levodopa-entacapone-carbidopa (Lecigon®) in pazienti con malattia di Parkinson avanzata in cure di routine

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

Panoramica dello studio

Descrizione dettagliata

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients

Tipo di studio

Osservativo

Iscrizione (Effettivo)

312

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Graz, Austria, 8036
        • Universitätsklinik für Neurologie, Medizinische Universität Graz
      • Hermagor, Austria, 9620
        • Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
      • Innsbruck, Austria, 6020
        • Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
      • Linz, Austria, 4020
        • Kepler Universitätsklinikum
      • Bruges, Belgio, 8000
        • AZ Sint-Jan
      • Edegem, Belgio, 2650
        • Antwerp University Hospital
      • Ghent, Belgio
        • Ghent University Hospital
      • Liège, Belgio
        • University Hospital Liege
      • Tournai, Belgio, 7500
        • Centre Hospitalier de Wallonie picarde (Chwapi)
      • Sofia, Bulgaria, 1113
        • Sveti Naum
      • Brno, Cechia
        • Masaryk university
      • Olomouc, Cechia
        • Fakultní nemocnice Olomouc
      • Osijek, Croazia, 31000
        • UHC Osijek, J. Klinici za neurologiju
      • Rijeka, Croazia
        • University Hospital Centre Rijeka (KBC Rijeka)
      • Zagreb, Croazia, 10000
        • University Hospital Centre (KBC Zagreb)
      • Zagreb, Croazia, 10000
        • Klinička bolnica Dubrava
      • Copenhagen, Danimarca, 2400
        • Bispebjerg Hospital
      • Bad Segeberg, Germania, 23795
        • Segeberger Kliniken GmbH Neurologisches Zentrum
      • Beelitz-Heilstätten, Germania, 14547
        • Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
      • Berlin, Germania, 10117
        • Charité - Universitätsmedizin Berlin
      • Cologne, Germania
        • Uniklinik Köln
      • Coppenbrügge, Germania, 31863
        • Krankenhaus Lindenbrunn
      • Essen, Germania, 45147
        • Klinik für Neurologie - Universitätsklinikum Essen
      • Freiburg im Breisgau, Germania, 79106
        • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
      • Göttingen, Germania, 37075
        • Zentrum für Seltene Erkrankungen Göttingen
      • Marburg, Germania, 35043
        • Universitätsklinikum Giessen und Marburg
      • Oldenburg, Germania, 26122
        • Evangelisches Krankenhaus Oldenburg
      • Osnabrück, Germania, 49076
        • Klinikum Osnabrück GmbH Klinik für Neurologie
      • Tübingen, Germania, 72076
        • Universitätsklinikum Tübingen
      • Ulm, Germania, 89081
        • RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
      • Wolfach, Germania, 77709
        • Parkinson-Klinik Ortenau
      • Dublin, Irlanda, D07 R2WY
        • The Dublin Neurological Institute, Mater Hospital
      • Dublin, Irlanda, D04 T6F4
        • St. Vincent's University Hospital
      • Groningen, Olanda, 97139713
        • University Medical Center Groningen
      • Brasov, Romania, 500326
        • Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
      • Bucharest, Romania, 050098
        • Bucharest University Emergency Hospital
      • Bucharest, Romania
        • Fundeni Clinical Institute
      • Bucharest, Romania, 011461
        • Spitalul Universitar de Urgență Elias
      • Bucharest, Romania, 020125
        • Colentina Hospital Bucharest
      • Cluj-Napoca, Romania, 400347
        • County Emergency Hospital Cluj-Napoca
      • Constanța, Romania, 900591
        • County Clinical Emergency Hospital of Constanta
      • Timișoara, Romania, 300723
        • Timiş County Emergency Clinical Hospital- Neurology 1
      • Timișoara, Romania, 300723
        • Timiş County Emergency Clinical Hospital
      • Târgu Mureş, Romania, 540136
        • Emergency County Hospital Targu Mures
      • Ljubljana, Slovenia, 1000
        • Department of Neurology, University Medical Centre
      • Maribor, Slovenia, 2000
        • Univerzitetni klinični center Maribor
      • Barcelona, Spagna, 08025
        • Hospital de la Santa Creu i Sant Pau
      • Madrid, Spagna, 28040
        • Hospital Clínico San Carlos
      • Madrid, Spagna, 28034
        • Hospital Universitario Ramón y Cajal
      • Madrid, Spagna
        • Hospital de la Princesa
      • Seville, Spagna, 41013
        • Hospital Virgen del Rocio
      • Gothenburg, Svezia, 413 45
        • Sahlgrenska University Hospital
      • Lund, Svezia
        • Skånes universitetssjukhus Lund
      • Uppsala, Svezia, 751 85
        • Uppsala university hospital
      • Budapest, Ungheria
        • Semmelweis Egyetem Neurológiai Klinika Budapest
      • Pécs, Ungheria, 7623
        • Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
      • Szeged, Ungheria, 6725
        • SZTE Szent-Györgyi Albert Klinikai Közpon

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Treating physician's normal patient pool

Descrizione

Inclusion Criteria:

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion Criteria:

  • Patients with contraindications as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

24 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

24 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
Lasso di tempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 luglio 2021

Completamento primario (Stimato)

7 ottobre 2026

Completamento dello studio (Stimato)

7 ottobre 2026

Date di iscrizione allo studio

Primo inviato

29 luglio 2021

Primo inviato che soddisfa i criteri di controllo qualità

3 settembre 2021

Primo Inserito (Effettivo)

14 settembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi